Print Page     Close Window     

Investors & Media

Corporate Profile

Seres Therapeutics, Inc. is a microbiome therapeutics platform company developing a novel class of biological drugs, which we refer to as Ecobiotic microbiome therapeutics, that are designed to restore health by repairing the function of a dysbiotic microbiome. The Company’s lead product candidate, SER-109, is intended to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon, and, if approved by the FDA, could be a first-in-field drug. Using its... More

Recent NewsMore
Seres Therapeutics Reports Positive Topline Results from SER-287 Phase 1b Study in Patients with Ulcerative Colitis
– SER-287 microbiome treatment resulted in a dose-dependent benefit in clinical remission rates, and an improvement in endoscopic scores – – No clinically significant safety or tolerability findings were observed – – Company intends to rapidly advance SER-287 to further development for Ulcerative Colitis – – Conference call scheduled for 8 a.m. today – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 2, 2017-- In the tabl... 
Seres Therapeutics to Present at the Baird 2017 Global Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 31, 2017-- Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced it will present at the Baird 2017 Global Healthcare Conference in New York, NY on Wednesday, September 6 at 10:50 a.m. ET. A live audio webcast of the presentation will be available under the “Investors and Media” section of Seres’ website. A replay of the presentation will become available approximately one hour after the event... 
Seres Therapeutics Reports Second Quarter 2017 Financial Results and Provides Update on Operational Progress
There are currently no upcoming events scheduled.
Stock Quote
 + 0.12 (1.11%)
10/17/17 4:00 p.m. ET
Refresh quote
E-mail Alerts
Sign up to receive e-mail alerts whenever Seres Therapeutics, Inc. posts new information to the site. Just enter your e-mail address and click Submit.
Request Information

Obtain investor relations information by contacting us.

Data provided by Nasdaq. Minimum 15 minutes delayed.

© Seres Therapeutics. All Rights Reserved.